Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

(Loss)/Earnings per Share (Tables)

v3.22.2
(Loss)/Earnings per Share (Tables)
 12 Months Ended
Mar. 31, 2022
Earnings per share [abstract]  
Schedule of (Loss)/Earnings Per Share

 

 

Year Ended March 31,

 

 

 

2022

 

 

2021

 

(Loss)/profit for the year attributable to Virax

 

 

(1,708,827

)

 

 

(650,984

)

Basic (loss)/earnings per share attributable to Virax – Class A

 

 

(0.67

)

 

 

(0.41

)

Diluted (loss)/earnings per share attributable to Virax – Class A

 

 

(0.67

)

 

 

(0.41

)

Basic (loss)/earnings per share attributable to Virax – Class B

 

 

(0.24

)

 

 

(0.79

)

Diluted (loss)/earnings per share attributable to Virax – Class B

 

 

(0.24

)

 

 

(0.79

)
Schedule of Diluted (Loss)/Earnings Per Share

Diluted (loss)/earnings per share is calculated by adjusting the weighted average number of ordinary shares in issue during the year to assume conversion of all dilutive potential ordinary shares. The Company had no dilutive shares as of March 31, 2022 and 2021.

 

 

 

As of March 31,

 

 

 

2022

 

 

2021

 

Weighted average number of ordinary shares used in basic income per share
   (Class A ordinary shares)

 

 

2,550,773

 

 

 

1,581,443

 

Weighted average number of ordinary shares used in basic income per share
   (Class B ordinary shares)

 

 

7,012,487

 

 

 

823,399

 

Weighted average number of ordinary shares used as the denominator in
   calculating basic (ss)/earnings per share

 

 

2,550,773

 

 

 

1,581,443

 

Weighted average number of ordinary shares and potential ordinary shares used
   as the denominator in calculating diluted (loss)/earnings per share(1)

 

 

2,550,773

 

 

 

1,581,443

 

____________

(1)
For the years ended March 31, 2022 and 2021, potential ordinary shares are anti-dilutive, as their inclusion in the diluted loss per share calculation would reduce the loss per share, and hence have been excluded.